Omega Therapeutics Inc. (OMGA)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
OMGA Chart
Omega Pacific Announces Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2025) - Omega Pacific Resources Ltd. (CSE: OMGA) ("Omega Pacific" or the "Company") is pleased to announce a non-brokered private placement financing of up to $1,975,000 (the "Offering") to support its 2025 exploration initiatives at the Williams Property, located in the very active Toodoggone District in northern British Columbia, Canada.
Omega Pacific Outlines 2025 Exploration Program in the Revitalized Toodoggone District
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2025) - Omega Pacific Resources Ltd. (CSE: OMGA) ("Omega Pacific" or the "Company") is pleased to announce its 2025 exploration strategy for the Williams Property, located in British Columbia's Toodoggone District.
Omega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams Property
VANCOUVER, BC / ACCESSWIRE / December 4, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) ("Omega Pacific" or the "Company") is pleased to announce final drill results from its 2024 drill program at the Williams Property in British Columbia's Golden Horseshoe. Drill hole WM24-03 returned multiple zones of gold mineralization with local high grades west of discovery hole WM22-02 (ext) (Figure 1).
Omega Therapeutics Inc. Dividends
Omega Therapeutics Inc. Earnings
| 20 Jun 2025 (3 Days) Date | | - Cons. EPS | - EPS |
| 15 Nov 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
| 20 Jun 2024 Date | | - Cons. EPS | - EPS |
| 6 Jun 2024 Date | | - Cons. EPS | - EPS |
| 20 Jun 2025 (3 Days) Date | | - Cons. EPS | - EPS |
| 15 Nov 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
| 20 Jun 2024 Date | | - Cons. EPS | - EPS |
| 6 Jun 2024 Date | | - Cons. EPS | - EPS |
Omega Therapeutics Inc. (OMGA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Omega Therapeutics Inc. ever had a stock split?
Omega Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Kaan Certel Ph.D. CEO | NASDAQ (NGS) Exchange | 68217N105 Cusip |
| US Country | 93 Employees | - Last Dividend | - Last Split | 30 Jul 2021 IPO Date |
Overview
Omega Therapeutics, Inc. is a pioneering force in the field of biotechnology, focusing on the clinical-stage development of novel therapies. Founded in 2016 and based in Cambridge, Massachusetts, the company has dedicated itself to leveraging its proprietary OMEGA platform. This cutting-edge platform targets the control of key epigenetic processes, aiming to address the underlying causes of various diseases by modifying gene expression without changing the DNA sequence itself. Through this innovative approach, Omega Therapeutics seeks to revolutionize the treatment landscape for a multitude of conditions.
Products and Services
OTX-2002 - Developed for treating hepatocellular carcinoma, this product is a testament to Omega Therapeutics' commitment to targeting serious and difficult-to-treat cancers through its innovative epigenetic modulation techniques.
OTX-2101 - Aiming at non-small cell lung cancer, OTX-2101 represents another facet of the company's focus on utilizing epigenetic controllers to manage cancer. This development underscores the versatility of the company's platform in addressing various types of malignancies.
Omega Epigenomic Controllers (OEC) - Designed for a variety of indications including inflammatory lung diseases (such as neutrophilic asthma and acute respiratory distress syndrome), dermatological conditions, oncology, and rheumatological diseases. The OECs embody Omega Therapeutics' ambition to tackle a broad spectrum of diseases by rectifying aberrant gene expression.
OEC candidates for idiopathic pulmonary fibrosis - Extending their epigenetic innovations to fibrotic diseases, these candidates are being developed to target the fibrosis and scarring in the lungs characteristic of idiopathic pulmonary fibrosis, further exemplifying the company's versatile approach to disease management.
Liver Regeneration Medicines - Reflecting the breadth of Omega Therapeutics' portfolio in regenerative medicine, these products aim to harness the power of epigenetic modulation for liver regeneration, offering new hope for liver disease patients.
OEC candidates for diabetes and other conditions to treat corneal epithelial injury - Highlighting the company's foray into ophthalmological and metabolic diseases, these candidates are designed to utilize epigenetic controllers to address corneal injuries, showcasing the potential breadth of the OMEGA platform's applications.
OEC candidates for the treatment of alopecia - Addressing the dermatological condition characterized by non-scarring hair loss, these candidates aim to provide novel treatments for alopecia, further diversifying Omega Therapeutics’ therapeutic offerings.
Contact Information
